DermTech Inc

$6.27 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About DermTech Inc

DermTech, Inc. is a molecular dermatology company that focuses on skin cancer. The Company develops products that facilitate the early detection of skin cancers, assess inflammatory diseases and customize drug treatments. The Company provides Adhesive Skin Collection Kit, which is designed to collect stratum corneum tissues of the skin from all locations of the body, with the exception of mucosals surfaces, palmar and plantar surfaces, and areas with excessive non-vellus hair. It provides Pigmented Lesion Assay (PLA), which assesses pigmented skin lesions, moles or dark skin spots for melanoma. It offers Nevome, which is the test to non-invasively identify pigmented lesions by analyzing known deoxyribonucleic acid (DNA) mutation risk factors for melanoma. The Company is also engaged in developing gene expression assays to identify cytokine inflammatory profiles that assist clinicians in guiding therapy. It also offers ResponseTNF product and CytokineEx 17 product.

Stock Analysis

last close $6.27
1-mo return 7.2%
3-mo return -3.5%
avg daily vol. 1.02M
52-week high 38.97
52-week low 4.18
market cap. $253M
forward pe -
annual div. -
roe -40.6%
ltg forecast -
dividend yield -
annual rev. $13M
inst own. 69.6%
baraka

Subscribe now for daily local and international financial news

Subscribe